{
    "clinical_study": {
        "@rank": "63722", 
        "acronym": "WADCH", 
        "arm_group": {
            "arm_group_label": "Warfarin Using Group"
        }, 
        "biospec_descr": {
            "textblock": "Samples with DNA frozen in -80\u2103"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in\n           Chinese patients\n\n        2. Drug: Warfarin\n\n        3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm\n           calculated dose and actual dose in the Chinese patients.\n\n        4. Hypothesis:Pharmacogenomic algorithm guided dose can help to  predict warfarin dose in\n           Chinese patients."
        }, 
        "brief_title": "The Study of Warfarin Maintenance Dose in Chinese Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Heart Valve Disease", 
            "Pulmonary Artery Embolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Embolism", 
                "Heart Valve Diseases", 
                "Pulmonary Embolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  For the patients who need to use warfarin, detect the \"Vitamin K epoxide reductase\n           complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2\n           (CYP4F2) genotype.\n\n        -  Record the demographic information: gender, age, height, and weight.\n\n        -  Record drug combination, complications, and international normalized ratio (INR), liver\n           function and kidney function or other biochemical test results.\n\n        -  Put genotypes, demographic information and other clinical information into the\n           algorithm to calculate warfarin dose for the patients, and compared with the actual\n           dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chinese patients\n\n          -  Age >18y\n\n          -  target INR 1.5~3.0\n\n          -  Patients signed informed consent\n\n        Exclusion Criteria:\n\n          -  Has  hemorrhage disease, or tendency to significant bleeding\n\n          -  Severe liver and kidney disfunction, serious infections, severe heart failure (NYHA\n             heart function classification \u2162 magnitude), severe pulmonary hypertension, abnormal\n             thyroid function, respiratory failure, anemia, malignant tumor, blood disease\n\n          -  patients with pregnancy or lactation;\n\n          -  with cognitive impairment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Chinese Han population who need to use Warfarin and older than 18 years old."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855737", 
            "org_study_id": "2011-GZH1"
        }, 
        "intervention": {
            "arm_group_label": "Warfarin Using Group", 
            "description": "Prescribe warfarin to the patients who are needed.", 
            "intervention_name": "Warfarin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Manufacturer: Orion Corporation", 
                "Product Name: Warfarin", 
                "3mg*100"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gene guided", 
            "warfarin dose", 
            "Chinese"
        ], 
        "lastchanged_date": "June 2, 2013", 
        "location": {
            "contact": {
                "email": "lchyl_fuwai@sina.com", 
                "last_name": "Yishi Li, MD, PhD", 
                "phone": "+86 10 88398395"
            }, 
            "contact_backup": {
                "email": "hyl0109@gmail.com", 
                "last_name": "Yiling Huang, MS", 
                "phone": "+86 10 88398395"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100037"
                }, 
                "name": "Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"
            }, 
            "investigator": [
                {
                    "last_name": "Yan Li, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ying Lou, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients", 
        "overall_contact": {
            "email": "winterliucn@gmail.com", 
            "last_name": "Hong Liu, MS", 
            "phone": "+86 10 88398547"
        }, 
        "overall_contact_backup": {
            "email": "sophialiyan1987@gmail.com", 
            "last_name": "Yan Li, MD", 
            "phone": "+86 10 88396298"
        }, 
        "overall_official": [
            {
                "affiliation": "Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College", 
                "last_name": "Yishi Li, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College", 
                "last_name": "Hong Liu, MS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of the patients whose predicted dose were within 20% of the actual maintenance dose.", 
            "measure": "The accuracy of the pharmacogenomics algorithm for warfarin maintenance dose", 
            "safety_issue": "No", 
            "time_frame": "one month after the initial dose of warfarin"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855737"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiovascular Institute & Fuwai Hospital", 
            "investigator_full_name": "Hong Liu", 
            "investigator_title": "Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Cardiovascular Institute & Fuwai Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiovascular Institute & Fuwai Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}